Scp 776
Alternative Names: Scp-776Latest Information Update: 22 Oct 2022
At a glance
- Originator Silver Creek Pharmaceuticals
- Class Heart failure therapies; Neuroprotectants; Recombinant fusion proteins; Urologics; Vascular disorder therapies
- Mechanism of Action Growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
- Preclinical Heart failure; Kidney disorders
Most Recent Events
- 21 Oct 2022 Phase-I clinical trials in Stroke in USA (IV) prior to 21 October 2022 (Silver Creek Pharmaceuticals pipeline, October 2022)
- 21 Oct 2022 Preclinical trials in Heart failure in USA (IV)prior to 21 October 2022 (Silver Creek Pharmaceuticals pipeline, October 2022)
- 21 Oct 2022 Preclinical trials in Kidney disorders in USA (IV) prior to 21 October 2022 (Silver Creek Pharmaceuticals pipeline, October 2022)